Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 34-year-old woman is seeking effective hair concealers for thinning hair, having tried various medications like spironolactone and oral minoxidil without success. Recommendations include Boldify hairline powder and products like Hairo or Kerablend.

A user shared their four-year hair regrowth progress using a regimen of Kirkland Minoxidil foam, Dutasteride, a derma roller, Nizoral shampoo, multivitamins, and a healthy lifestyle. They started seeing significant results after a year with no side effects reported.

The conversation discusses cost-effective options for hair loss treatments, specifically oral dutasteride and 5 mg minoxidil from Cost Plus Pharmacy, and compares prices with other pharmacies like Costco and Amazon. The focus is on encouraging affordable treatment options to avoid high costs from brands like Nutrafol or HIMS.

Amazon offers a convenient and affordable way to get a finasteride prescription with just two photos, costing $29 for the prescription and $17.60 for a 90-day supply. Users discuss various telehealth options and pricing for finasteride and dutasteride, highlighting Amazon's RX pass as a cost-effective choice.

Topical finasteride and Minoxidil are the most effective treatments for hair loss, with non-pharmaceutical options like PRP, stem cell therapy, and red light caps offering minimal additional benefits. Users suggest sticking to proven treatments unless cost is not a concern.

The user has been using minoxidil for almost 6 months and finasteride for almost 4 months, experiencing significant shedding and minimal stabilization. They are considering switching to dutasteride if no improvements are seen and are advised to be patient, as results may take up to 2 years.

The user experienced regrowth and stabilization in hair density using finasteride, minoxidil, a derma roller, and an LLLT helmet, but noticed a recent decline in hair quality. They only take finasteride orally and are unsure about the effectiveness of the LLLT device.

The post shows monthly progress photos of hair regrowth using minoxidil and finasteride. Users comment positively on the visible improvement.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The shed phase from using finasteride and minoxidil can vary, with some experiencing noticeable hair loss and others having minimal shedding. Despite initial shedding, many users report eventual hair regrowth and improvement, making the treatment worthwhile.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

A 48-year-old male from the Philippines shared his two-year progress using finasteride only for hair regrowth, experiencing significant improvement without minoxidil. He started with 0.5mg and increased to 1.25mg, later adjusting to every other day due to elevated liver enzymes, and reported 90% hair restoration.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

The user is taking a 2-in-1 pill containing 1mg finasteride and 3mg minoxidil daily, noticing some hair thickening and new hair growth but minimal progress at the back of the head. They are considering adding topical minoxidil or increasing dosage and are unsure if they should change their routine or wait for more results.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.

The user has been using oral finasteride, topical minoxidil, and a dermaroller for hair regrowth, noticing most improvement between months 3 and 4. Other users commented on the positive results and shared their own treatment routines.

A user shared their progress with hair loss treatment using 0.1% topical finasteride for 5 months and 6% minoxidil for 2 months, reporting reduced hair shedding, less scalp visibility, and healthier hair. They experienced no significant side effects except initial itching and dandruff, and noted an increase in libido.

The user is experiencing worsening hair loss despite using oral finasteride, oral minoxidil, microneedling, keto shampoo, and supplements for seven months. They are concerned about continued shedding and lack of regrowth, and are considering adding topical minoxidil to their routine.

Some users experience worsening hair loss with dutasteride and improvement after switching back to finasteride, while others find better results with dutasteride. The effectiveness of treatments like finasteride, dutasteride, minoxidil, and RU58841 varies, requiring individuals to try different combinations or dosages to find what works best.

The conversation is about finding online pharmacies to obtain tretinoin for hairline improvement, with suggestions including Amazon and nurx.com. Alternatives like adapalene are also mentioned.